Relationship between Bone Density and Biochemical Markers of Bone among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd
Keywords:
Epilepsy, Sodium Valproate, Carbamazepine, Bone DensityAbstract
Introduction: Chronic antiepileptic therapy has been associated with metabolic bone diseases including osteomalacia and osteoporosis. The aim of this study was to determine frequency of changes in biochemical and bone mineral density (BMD) in adults receiving valproaic acid (VPA) & carbamazepine (CBZ).
Methods: In a cross sectional study evaluating adults (age 20- 50 y) epileptic patients receiving valproic acid or carbamazepine for at least 2 years. This study was conducted from May 2014 to May 2015 in Shahid Sadoughi Hospital of Yazd University of Medical Science, Yazd, Iran. Bone metabolism was evaluated by measurement of serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP) and parathormone hormone (PTH), BMD at lumbar and femoral measured by dual energy X ray absorptiometry (DXA). SPSS software (version 18) was used for data analysis. The t-test was used for quantitative data, and the chi-squared test was used for the qualitative variables.
Results: Eighty two epileptic patients (mean age: 31.67±10.69 year) treated with either carbamazepine (n=41) or valproate sodium (n=41) were studied. Normal serum Ca and P levels were observed in 98.8% and 97.6% of patients respectively. Serum ALP and PTH were normal in 97.6% and 97.6% of patients. Means of Ca and P in CBZ group were significantly lower than VPA group (Ca: 9.02 vs. 9.1, p-value: 0.03 and P: 3.54 vs. 3.76 p- value: 0.004). BMD values at lumbar spine were not significant in either group (T. score CBZ: -0.43± 0.744 vs. T. score VPA: -0.615± 0.904 and p-value: 0.333) and were significantly higher than Iranian normal population BMD value at femoral neck in CBZ group was lower than VPA group (T. score CBZ: -0.707± 0.896 vs. T. score VPA: - 0.297± 0.850 p-value: 0.04). Dosage of CBZ and VPA did not correlate with BMD and biochemical parameters. Duration of CBZ use had correlation with increased ALP and duration of VPA use had correlation with decreased BMD in adult patients.
Conclusion: long term anti-epileptic drug treatment either with CBZ and VPA which has unknown effects on skeletal mineralization and induces a state of decreased bone mineral density BMD values at femoral neck were significant in CBZ group Therefore regular screening for monitoring of biochemical markers of bone turnover and BMD with DXA during the treat period is recommended. In addition, Ca supplement could be considered for all patients with epilepsy upon initiation of CBZ and VPA therapy.
References
Ashrafi M, Khoshhal F, Rabani A, Salajegheh N, Nasab AM, Shams S, et al. Study of Antiepileptic Drugs
effects on bone metabolism. Iranian Journal of Pediatrics. 2005;15(4):347-52.
Eizadi-Mood N, Yaraghi A, Gheshlaghi F, Mogiri R. Poison-induced seizures in 66 patients: Causes,
treatments and outcomes. Tehran University Medical Journal. 2008;66(3):214-20.
Beattie K, Phadke G, Novakovic J. Lamotrigine. Profiles of drug substances, excipients, and related
methodology. 2012;37:245-85. doi: 10.1016/B978-0-12-397220-0.00006-4, PMid: 22469320
Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy & Behavior. 2004;5:24-9. doi:
1016/j.yebeh.2003.11.029, PMid: 15123008
Petty SJ, O’brien T, Wark J. Anti-epileptic medication and bone health. Osteoporosis international.
;18(2):129-42. doi: 10.1007/s00198-006-0185-z, PMid: 17091219
Valsamis HA, Arora SK, Labban B, McFarlane SI. Antiepileptic drugs and bone metabolism. Nutrition &
metabolism. 2006;3(1):36. doi: 10.1186/1743-7075-3-36, PMid: 16956398, PMCid: PMC1586194
Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure.
;17(2):181-6. doi: 10.1016/j.seizure.2007.11.020, PMid: 18187347
Triantafyllou N, Lambrinoudaki I, Armeni E, Evangelopoulos E-M, Boufidou F, Antoniou A, et al. Effect
of long-term valproate monotherapy on bone mineral density in adults with epilepsy. Journal of the
neurological sciences. 2010;290(1):131-4. doi: 10.1016/j.jns.2009.12.015, PMid: 20056251
Pellock JM. Carbamazepine side effects in children and adults. Epilepsia. 1987;28(s3):S64-S70. doi:
1111/j.1528-1157.1987.tb05780.x, PMid: 2961558
Ashjazadeh N, Zamani A, Pourjafar M, Omrani GR. Bone density of ambulatory adult patients receiving
long-term anticonvulsant drug therapy. Arch Iran Med. 2009;12(6):550-4. PMid: 19877746
Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F. Bone and calcium metabolism and antiepileptic
drugs. Clinical neurology and neurosurgery. 2010;112(1):1-10. doi: 10.1016/j.clineuro.2009.10.011, PMid:
Sheth RD. Bone health in pediatric epilepsy. Epilepsy & Behavior. 2004;5:30-5. doi:
1016/j.yebeh.2003.11.025, PMid: 15123009
Babayigit A, Dirik E, Bober E, Cakmakcı H. Adverse effects of antiepileptic drugs on bone mineral
density. Pediatric neurology. 2006;35(3):177-81. doi: 10.1016/j.pediatrneurol.2006.03.004, PMid:
Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy & Behavior. 2004;5:41-7.
doi: 10.1016/j.yebeh.2003.11.028, PMid: 15123011
Boluk A, Guzelipek M, Savlı H, Temel I, Ozışık HI, Kaygusuz A. The effect of valproate on bone mineral
density in adult epileptic patients. Pharmacological research. 2004;50(1):93-7. doi:
1016/j.phrs.2003.11.011, PMid: 15082034
Tsukahara H, Kimura K, Todoroki Y, Ohshima Y, Hiraoka M, Shigematsu Y, et al. Bone mineral status in
ambulatory pediatric patients on long ‐ term anti ‐ epileptic drug therapy. Pediatrics international.
;44(3):247-53. doi: 10.1046/j.1442-200X.2002.01561.x, PMid: 11982890
ıdvan Akın R, Okutan V, Sarıcı Ü, Altunbaş A, Gökçay E. Evaluation of bone mineral density in children
receiving antiepileptic drugs. Pediatric neurology. 1998;19(2):129-31. doi: 10.1016/S0887-8994(98)00039- 3
Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal,
and postpubertal patients receiving carbamazepine. Epilepsia. 2002;43(12):1488-92. doi: 10.1046/j.1528- 1157.2002.13002.x, PMid: 12460249
Beniczky SA, Viken J, Jensen LT, Andersen NB. Bone mineral density in adult patients treated with
various antiepileptic drugs. Seizure. 2012;21(6):471-2. doi: 10.1016/j.seizure.2012.04.002, PMid:
Erbayat Altay E, Serdaroğlu A, Tümer L, Gücüyener Κ, Hasanoğlu A. Evaluation of bone mineral
metabolism in children receiving carbamazepine and valproic acid. Journal of Pediatric Endocrinology and
Metabolism. 2000;13(7):933-40. doi: 10.1515/JPEM.2000.13.7.933, PMid: 10968482
Fuleihan GE-H, Dib L, Yamout B, Sawaya R, Mikati MA. Predictors of bone density in ambulatory
patients on antiepileptic drugs. Bone. 2008;43(1):149-55. doi: 10.1016/j.bone.2008.03.002, PMid:
Ecevit C, Aydogan A, Kavakli T, Altinoz S. Effect of carbamazepine and valproate on bone mineral
density. Pediatr Neurol. 2004;31(4):279-82. doi: 10.1016/j.pediatrneurol.2004.03.021, PMid: 15464641
Sheth RD, Wesolowski CA, Jacob J, Penney S, Hobbs GR, Riggs JE, et al. Effect of carbamazepine and
valproate on bone mineral density. The Journal of pediatrics. 1995;127(2):256-62. doi: 10.1016/S0022- 3476(95)70304-7
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
